Shared on04 Aug 25Fair value Decreased 48%
The sharp decline in Zynex’s price target is primarily driven by a shift from modest revenue growth to contraction alongside a higher discount rate, resulting in a revised fair value of $2.85. What's in the News Steven Dyson appointed CEO, succeeding Thomas Sandgaard, who will continue as Chairman and Chair of the Technology Committee; Dyson brings over 25 years’ experience in medical technology and private equity.
Shared on23 Apr 25Fair value Increased 18%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 37%
AnalystConsensusTarget has decreased future PE multiple from 24.1x to 15.1x.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 5.45%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 14%
AnalystConsensusTarget has decreased revenue growth from 19.5% to 1.4%, increased profit margin from 10.6% to 13.0%, increased future PE multiple from 19.7x to 23.5x and increased discount rate from 7.4% to 8.4%.
Shared on11 Mar 25Fair value Increased 213%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.